News und Analysen

Methode Electronics (NYSE:MEI), a global manufacturer of mechatronic and electronic solutions serving the automotive, industrial, and interface markets, released its fiscal first quarter 2026

Lakeland (NASDAQ:LAKE) reported fiscal second quarter 2026 earnings on September 3, 2025, posting record revenue of $52.5 million, up 36% year-over-year driven largely by fire services growth and

Shares of UnitedHealth Group (NYSE: UNH) are rising on Tuesday, up 8.8% as of 2:23 p.m. ET. The jump comes as the S&P 500 and the Nasdaq Composite ticked up slightly.

The struggling healthcare

In this video, I will cover the recent updates regarding Advanced Micro Devices (NASDAQ: AMD). Watch the short video to learn more, consider subscribing, and click the special offer link below.

A rocky road for Summit Therapeutics got a lot rougher over the weekend. The company presented somewhat disappointing data for the experimental cancer drug it's developing.

When the market opened on

The old proverb "patience is a virtue" is very true in the world of investing. Investors who aren't scared off by a struggling stock, have the ability to see the company's long-term potential, and

Quick -- what were you doing back in September of 2022? Were you buying $10,000 of stock in Amgen (NASDAQ: AMGN)? If so, you might be wondering what that's worth today. Even if you didn't buy Amgen

For decades, UnitedHealth Group (NYSE: UNH) could do no wrong. The company raised its dividend by an exceptional 7,266% from 2010 to 2025, while shares rose as much as 1,700% during this run.

But

With patent-protected market exclusivity for their products, pharmaceutical companies reliably produce profits that they aren't shy about distributing to shareholders. In an industry already known

The market was less than impressed with the top-line results from Viking Therapeutics' (NASDAQ: VKTX) phase 2 trial of an oral formulation of its anti-obesity drug VK2735. The disappointment created

Pfizer (NYSE: PFE) is a fairly well-known drugmaker, with a name that even non-healthcare-oriented types would likely know. That's a testament to the company's longevity and its success as a

Investors haven't been kind to Intuitive Surgical (NASDAQ: ISRG) and Regeneron Pharmaceuticals (NASDAQ: REGN) this year. Both healthcare leaders have encountered company-specific issues that have

What's one of the biggest mistakes investors make? Selling stocks too soon. It's smarter to try to adhere to Warren Buffett's favorite holding period of "forever," or at least as close to that goal

Explore the exciting world of UnitedHealth (NYSE: UNH) with our contributing expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights into market

BioNTech (NASDAQ: BNTX), the Germany-based biotech that scored big early in the pandemic era with the Comirnaty vaccine it developed with Pfizer, had some fresh news from the lab to report on

Nektar Therapeutics (NASDAQ: NKTR) stock surged by more than 20% in the week to Friday morning. The move wasn't so much caused by anything specific to Nektar's drug development program. Instead

Dividend stocks that offer high yields can be gold mines for your portfolio as they can generate loads of recurring income for you for years. Whether you want to use the money to reinvest in those

Just because a stock has been battered doesn't make it an automatic buy. That's only the case if it can bounce back, and in some cases, there are few good reasons to believe it can.

Take Teladoc

Shares in Arrowhead Pharmaceuticals (NASDAQ: ARWR) rose by more than 27% in the week to Friday morning. The company's bold aim is to have "20 individual products, either partnered or wholly owned

Most development in artificial intelligence (AI) happens inside data centers, which are filled with thousands of purpose-designed chips from suppliers like Nvidia, Advanced Micro Devices, and

Viking Therapeutics (NASDAQ: VKTX) has intrigued investors over the past year and a half because it's involved in a potential David and Goliath story. Today, pharma giants Eli Lilly and Novo Nordisk

There is no sugarcoating it: Vertex Pharmaceuticals (NASDAQ: VRTX) has faced significant issues this year that have sunk its stock price. The company's shares are down 2% year-to-date, while the S&P

The biotech industry can be highly volatile. Companies in the sector can sometimes see their shares double in a short period due to hitting important clinical milestones. Over a more extended